The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2023
Filed:
Nov. 01, 2017
Applicant:
Trillium Therapeutics Ulc, Mississauga, CA;
Inventors:
Emma Linderoth, Toronto, CA;
Natasja Nielsen Viller, Oakville, CA;
Robert Adam Uger, Richmond Hill, CA;
Penka Slavcheva Slavova-Petrova, Toronto, CA;
Assignee:
Pfizer Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 31/395 (2006.01); A61K 38/15 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1741 (2013.01); A61K 31/395 (2013.01); A61K 38/15 (2013.01); A61K 38/1709 (2013.01); A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 2317/76 (2013.01);
Abstract
CD47disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.